Oluyemi Okupe Sells 9,388 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,388 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $27.89, for a total transaction of $261,831.32. Following the sale, the chief financial officer directly owned 264,117 shares in the company, valued at $7,366,223.13. This trade represents a 3.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.09, for a total transaction of $1,943,389.47.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91.

Hims & Hers Health Trading Down 4.1%

Shares of HIMS stock traded down $1.19 on Tuesday, hitting $27.43. 7,895,463 shares of the company’s stock traded hands, compared to its average volume of 26,328,367. The stock has a market capitalization of $6.40 billion, a price-to-earnings ratio of -43.53 and a beta of 2.40. The company’s fifty day simple moving average is $32.14 and its 200 day simple moving average is $26.05. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same period in the prior year, the firm earned $0.17 earnings per share. The business’s revenue for the quarter was up 38.2% on a year-over-year basis. Equities analysts forecast that Hims & Hers Health, Inc. will post -0.05 EPS for the current year.

Analyst Upgrades and Downgrades

HIMS has been the subject of several analyst reports. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. JPMorgan Chase & Co. decreased their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a report on Tuesday, May 12th. Finally, Barclays raised their target price on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $32.43.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after buying an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health during the first quarter valued at approximately $30,000. EverSource Wealth Advisors LLC raised its holdings in shares of Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares in the last quarter. Amundi lifted its stake in Hims & Hers Health by 5.3% in the second quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after acquiring an additional 522 shares during the period. Finally, California Public Employees Retirement System lifted its stake in Hims & Hers Health by 9.5% in the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after acquiring an additional 29,471 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.